Evidence map›Paper›PMID 34233193›Full record

ArticleCell reports2021

Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy.

Eswari Dodagatta-Marri, Hsiao-Yen Ma, Benjia Liang, John Li, Dominique S Meyer, Szu-Ying Chen, Kai-Hui Sun, Xin Ren, Bahar Zivak, Michael D Rosenblum and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Molecular Mechanisms and Immune Regulation in Prostate Cancer: A Review.International journal of molecular sciences · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 2 countries.

Eswari Dodagatta-MarriHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Hsiao-Yen MaLung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Benjia LiangLung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China.
John LiLung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Dominique S MeyerHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Szu-Ying ChenHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Kai-Hui SunLung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Xin RenLung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Bahar ZivakDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
Michael D RosenblumDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
Mark B HeadleyDepartment of Pathology, University of California, San Francisco, San Francisco, CA, USA.
Lauren PinzasHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Nilgun I ReedLung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Joselyn S Del CidLung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Byron C HannHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Sharon YangComparative Medicine, Pfizer Inc., San Diego, CA, USA.
Anand GiddabasappaOncology Research Unit, Pfizer Inc., Pearl River, NY, USA.
Kavon NoorbeheshtOncology Research Unit, Pfizer Inc., Pearl River, NY, USA.
Bing YangOncology Research Unit, Pfizer Inc., Pearl River, NY, USA.
Joseph Dal PortoPfizer Centers for Therapeutic Innovation, San Francisco, CA, USA.
Tatsuya TsukuiLung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Kyle NiessenPfizer Centers for Therapeutic Innovation, San Francisco, CA, USA.
Amha AtakilitLung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Rosemary J AkhurstHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA; Department of Anatomy, University of California, San Francisco, San Francisco, CA, USA. Electronic address: rosemary.akhurst@ucsf.edu.
Dean SheppardLung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. Electronic address: dean.sheppard@ucsf.edu.
University of California, San Francisco · USPfizer (United States) · USShandong University · CN

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7M
Integrating targeted and immunotherapy to treat genetically heterogeneous cancersU01CA217864 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BALMAIN, ALLAN, KRUMMEL, MATTHEW F · 2017 to 2021
$5.1M
The Tumor Microenvironment Niche of Type I conventional Dendritic CellsR01CA197363 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHEW F KRUMMEL · 2017 to 2026
$4.5M
Advancing the translatability of mouse models for cancer immunotherapyR01CA210561 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AKHURST, ROSEMARY J · 2018 to 2021
$2.0M
Role of TH17 and IL17A in Acute Lung InjuryK08HL111208 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LI, JOHN T · 2012 to 2016
$709k
NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA197363NCI NIH HHS R01 CA210561NCI NIH HHS U01 CA217864NHLBI NIH HHS K08 HL111208
6 · The paper itself

Abstract

αvβ8 integrin, a key activator of transforming growth factor β (TGF-β), inhibits anti-tumor immunity. We show that a potent blocking monoclonal antibody against αvβ8 (ADWA-11) causes growth suppression or complete regression in syngeneic models of squamous cell carcinoma, mammary cancer, colon cancer, and prostate cancer, especially when combined with other immunomodulators or radiotherapy. αvβ8 is expressed at the highest levels in CD4+CD25+ T cells in tumors, and specific deletion of β8 from T cells is as effective as ADWA-11 in suppressing tumor growth. ADWA-11 increases expression of a suite of genes in tumor-infiltrating CD8+ T cells normally inhibited by TGF-β and involved in tumor cell killing, including granzyme B and interferon-γ. The in vitro cytotoxic effect of tumor CD8 T cells is inhibited by CD4+CD25+ cells, and this suppressive effect is blocked by ADWA-11. These findings solidify αvβ8 integrin as a promising target for cancer immunotherapy.

Indexed as

ImmunityImmunotherapyModels, BiologicalAnimalsAntibodies, NeoplasmCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationCTLA-4 AntigenGene Expression Regulation, NeoplasticGranzymesIntegrinsInterferon-gammaLymphocyte DepletionMaleAntibodies, NeoplasmCTLA-4 AntigenGranzymesintegrin alphavbeta8IntegrinsInterferon-gammaSmad3 ProteinTransforming Growth Factor betaTumor Necrosis Factor Receptor Superfamily, Member 9alphavbeta8anti-tumor immunityCD8 T cellsintegrinTGFbeta

Identifiers

PMID34233193
PMCPMC8321414
OpenAlexW3178899807

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.